CoChat

The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity

Open access
Fukuda, Makoto · 2021 · Diabetes
Cited by 69

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) (also known as gastric inhibitory polypeptide) is a hormone produced in the upper gut and secreted to the circulation in response to the ingestion of foods, especially fatty foods. Growing evidence supports the physiological and pharmacological relevance of GIP in obesity. In an obesity setting, inhibition of endogenous GIP or its receptor leads to decreased energy intake, increased energy expenditure, or both, eventually causing weight loss. Further, supraphysiological dosing of exogenous long-lasting GIP agonists alters energy balance and has a marked antiobesity effect. This remarkable yet paradoxical antiobesity effect is suggested to occur primarily via the brain. The brain is capable of regulating both energy intake and expenditure and plays a critical role in human obesity. In addition, the GIP receptor is widely distributed throughout the brain, including areas responsible for energy homeostasis. Recent studies have uncovered previously underappreciated roles of the GIP receptor in the brain in the context of obesity. This article highlights how the GIP receptor expressed by the brain impacts obesity-related pathogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dbi21-0001

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 50

  1. Holst, 2013, Is there a place for incretin therapies in obesity and prediabetes?, Trends Endocrinol Metab, 24, 145, 10.1016/j.tem.2013.01.004 · DOI
  2. Marks, 2020, The early history of GIP 1969-2000: from enterogastrone to major metabolic hormone, Peptides, 125, 170276, 10.1016/j.peptides.2020.170276 · DOI
  3. Creutzfeldt, 1978, Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels, Diabetologia, 14, 15, 10.1007/BF00429703 · DOI · Paper page
  4. Bailey, 1986, Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets, Acta Endocrinol (Copenh), 112, 224, 10.1530/acta.0.1120224 · DOI · Paper page
  5. Polak, 1975, Gastrointestinal apudosis in obese hyperglycaemic mice, Virchows Arch B Cell Pathol Incl Mol Pathol, 19, 135, 10.1007/BF02889363 · DOI
  6. Nasteska, 2014, Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions, Diabetes, 63, 2332, 10.2337/db13-1563 · DOI · Paper page
  7. Irwin, 2009, Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes, Biol Chem, 390, 75, 10.1515/BC.2009.002 · DOI · Paper page
  8. Montgomery, 2010, Active immunization against (Pro(3))GIP improves metabolic status in high-fat-fed mice, Diabetes Obes Metab, 12, 744, 10.1111/j.1463-1326.2010.01228.x · DOI · Paper page
  9. Nakamura, 2018, Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice, Obes Sci Pract, 4, 194, 10.1002/osp4.164 · DOI · Paper page
  10. Dorajoo, 2012, Replication of 13 obesity loci among Singaporean Chinese, Malay and Asian-Indian populations, Int J Obes (Lond), 36, 159, 10.1038/ijo.2011.86 · DOI
  11. Wen, 2012, Meta-analysis identifies common variants associated with body mass index in east Asians, Nat Genet, 44, 307, 10.1038/ng.1087 · DOI · Paper page
  12. Turcot, 2018, Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity, Nat Genet, 50, 26, 10.1038/s41588-017-0011-x · DOI · Paper page
  13. Woods, 1981, Peptides and the control of meal size, Diabetologia, 20, 305, 10.1007/BF00254497 · DOI
  14. Ambati, 2011, GIP-dependent expression of hypothalamic genes, Physiol Res, 60, 941, 10.33549/physiolres.932151 · DOI · Paper page
  15. NamKoong, 2017, Central administration of GLP-1 and GIP decreases feeding in mice, Biochem Biophys Res Commun, 490, 247, 10.1016/j.bbrc.2017.06.031 · DOI · Paper page
  16. Nauck, 2020, No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects, Peptides, 125, 170176, 10.1016/j.peptides.2019.170176 · DOI
  17. Rodríguez, 2010, The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid, Peptides, 31, 757, 10.1016/j.peptides.2010.01.003 · DOI · Paper page
  18. Hetherington, 1940, Hypothalamic lesions and adiposity in the rat, Anat Rec, 78, 149, 10.1002/ar.1090780203 · DOI · Paper page
  19. Farooqi, 2008, Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity, Nat Clin Pract Endocrinol Metab, 4, 569, 10.1038/ncpendmet0966 · DOI · Paper page
  20. Kaplan, 1994, Gastric inhibitory polypeptide (GIP) binding sites in rat brain, Peptides, 15, 297, 10.1016/0196-9781(94)90016-7 · DOI
  21. Regard, 2008, Anatomical profiling of G protein-coupled receptor expression, Cell, 135, 561, 10.1016/j.cell.2008.08.040 · DOI · Paper page
  22. Bates, 2012, Gipr is essential for adrenocortical steroidogenesis; however, corticosterone deficiency does not mediate the favorable metabolic phenotype of Gipr(−/−) mice, Diabetes, 61, 40, 10.2337/db11-1060 · DOI · Paper page
  23. Usdin, 1993, Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain, Endocrinology, 133, 2861, 10.1210/endo.133.6.8243312 · DOI · Paper page
  24. Lockie, 2012, Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling, Diabetes, 61, 2753, 10.2337/db11-1556 · DOI · Paper page
  25. Christensen, 2015, Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes, Int J Obes (Lond), 39, 1651, 10.1038/ijo.2015.136 · DOI
  26. Glage, 2011, Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats, Fluids Barriers CNS, 8, 18, 10.1186/2045-8118-8-18 · DOI
  27. Lee, 2013, CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer’s disease, J Alzheimers Dis Parkinsonism, 3, 128
  28. Nyberg, 2007, Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain, J Neurosci Res, 85, 2099, 10.1002/jnr.21349 · DOI · Paper page
  29. Adriaenssens, 2020, The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system, Peptides, 125, 170194, 10.1016/j.peptides.2019.170194 · DOI · Paper page
  30. Papatheodorou, 2018, Expression Atlas: gene and protein expression across multiple studies and organisms, Nucleic Acids Res, 46, D246, 10.1093/nar/gkx1158 · DOI · Paper page
  31. Zhang, 2020, GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models, Peptides, 125, 170184, 10.1016/j.peptides.2019.170184 · DOI · Paper page
  32. Ravn, 2013, Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor, J Biol Chem, 288, 19760, 10.1074/jbc.M112.426288 · DOI · Paper page
  33. Ryan, 2012, Central nervous system mechanisms linking the consumption of palatable high-fat diets to the defense of greater adiposity, Cell Metab, 15, 137, 10.1016/j.cmet.2011.12.013 · DOI · Paper page
  34. Könner, 2012, Selective insulin and leptin resistance in metabolic disorders, Cell Metab, 16, 144, 10.1016/j.cmet.2012.07.004 · DOI · Paper page
  35. Joo, 2017, Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet–fed mice, Diabetes, 66, 868, 10.2337/db16-0758 · DOI · Paper page
  36. Chen, 2015, Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice, Am J Physiol Endocrinol Metab, 308, E414, 10.1152/ajpendo.00418.2014 · DOI · Paper page
  37. Beaudry, 2019, Physiological roles of the GIP receptor in murine brown adipose tissue, Mol Metab, 28, 14, 10.1016/j.molmet.2019.08.006 · DOI · Paper page
  38. Ahlqvist, 2013, Link between GIP and osteopontin in adipose tissue and insulin resistance, Diabetes, 62, 2088, 10.2337/db12-0976 · DOI · Paper page
  39. Lamont, 2008, Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice, Diabetes, 57, 190, 10.2337/db07-1202 · DOI · Paper page
  40. Kaneko, 2016, Neuronal Rap1 regulates energy balance, glucose homeostasis, and leptin actions, Cell Rep, 16, 3003, 10.1016/j.celrep.2016.08.039 · DOI · Paper page
  41. Fukuda, 2011, Induction of leptin resistance by activation of cAMP-Epac signaling, Cell Metab, 13, 331, 10.1016/j.cmet.2011.01.016 · DOI · Paper page
  42. Gloerich, 2010, Epac: defining a new mechanism for cAMP action, Annu Rev Pharmacol Toxicol, 50, 355, 10.1146/annurev.pharmtox.010909.105714 · DOI · Paper page
  43. Sands, 2006, Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells, Mol Cell Biol, 26, 6333, 10.1128/MCB.00207-06 · DOI · Paper page
  44. Armstrong, 2020, The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY, Nucleic Acids Res, 48, D1006
  45. Maskery, 2020, The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of Alzheimer’s disease, Am J Alzheimers Dis Other Demen, 35, 1533317520953041, 10.1177/1533317520953041 · DOI · Paper page
  46. Siegel, 1985, Stimulation of insulin release in isolated rat islets by GIP in physiological concentrations and its relation to islet cyclic AMP content, Diabetologia, 28, 857, 10.1007/BF00291078 · DOI
  47. Amiranoff, 1984, Functional GIP receptors in a hamster pancreatic beta cell line, In 111: specific binding and biological effects, Biochem Biophys Res Commun, 123, 671, 10.1016/0006-291X(84)90281-X · DOI
  48. Cordonier, 2019, Luciferase reporter mice for in vivo monitoring and ex vivo assessment of hypothalamic signaling of Socs3 expression, J Endocr Soc, 3, 1246, 10.1210/js.2019-00077 · DOI
  49. Faivre, 2011, Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis, J Neurophysiol, 105, 1574, 10.1152/jn.00866.2010 · DOI · Paper page
  50. Tian, 2010, Active immunization with glucose-dependent insulinotropic polypeptide vaccine influences brain function and behaviour in rats, Scand J Immunol, 72, 1, 10.1111/j.1365-3083.2010.02400.x · DOI

Cited by

See all 69

Metadata

Authors
Fukuda, M.
Venue
Diabetes
Published
2021-06-27
Volume
70
Issue
9
Pages
1929-1937
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W3174702068
Cited by
69
References
37
FWCI
3.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.